The following represents a list of scientific presentations from the past 3 years. These publications are provided for individual, educational purposes for US healthcare professionals only and are not a substitute for consultation and review of reference materials and complete medical literature pertaining to an investigational compound or individual product. Please note that individual publications are only current as of the date listed and may be updated by additional data and/or publications. Please do not copy or distribute further. Further reproduction or distribution is strictly prohibited without permission from the copyright owner(s). Content may be subject to congress and publisher copyright permissions.
The scientific information may include data on investigational use(s) of compounds for which efficacy and safety have not been established.
European Hematology Association | Poster June 9, 2023
Avapritinib
Reductions in indolent systemic mastocytosis biomarker burden with avapritinib in the registrational, double-blind placebo-controlled PIONEER trial
European Hematology Association | Poster June 9, 2023
Avapritinib
Avapritinib in patients with advanced systemic mastocytosis (AdvSM): Efficacy and safety analyses from the phase 2 PATHFINDER study with 2-year follow-up
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 25, 2024
Avapritinib
Avapritinib Decreased Symptom Burden in Patients with Indolent Systemic Mastocytosis in the Registrational Double-Blind, Placebo-Controlled PIONEER Study
American Academy of Allergy, Asthma & Immunology (AAAAI) | Oral presentation February 25, 2024
Prevalence Of The KIT D816V Mutation In Peripheral Blood (PB) Of Patients With Evidence Of Systemic Mast Cell Activation (MCA): Results Of The Prospective, Multi-centered, Global PROSPECTOR Clinical Trial
American Academy of Allergy, Asthma & Immunology (AAAAI) | Oral presentation February 25, 2024
Exploring the Spectrum of Indolent Systemic Mastocytosis: Analysis of High-Risk Disease Features in the PIONEER Study
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 25, 2024
Reductions in Polypharmacy for Patients with Indolent Systemic Mastocytosis on Avapritinib
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 25, 2024
The Five Dimensions of the ISM Patient Experience – Uncovering the “Real-world” Experience of Patients with Indolent Systemic Mastocytosis
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 25, 2024
Quantifying Diagnostic Delays in Patients with Indolent and Aggressive Systemic Mastocytosis
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 25, 2024
Systemic Mastocytosis: Shedding Light on A Rare and Complicated Disease
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 25, 2024
Patient-Reported Outcome Measures in Systemic Mastocytosis: A Systematic Review
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 23,2024
BLU-808
BLU-808, a Potent and Selective Small Molecule Inhibitor of Wild-type c-KIT for Mast Cell Disorders
American Society of Hematology (ASH) Annual Meeting 2023 | Poster December 10, 2023
Development and External Validation of a Diagnostic Tool for the Earlier Detection of Patients
with Systemic Mastocytosis Presenting in a Real-World Community Hematology Setting
American Society of Hematology (ASH) Annual Meeting 2023 | Oral presentation December 9, 2023
BLU-263
Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the HARBOR Trial
American Society of Hematology (ASH) Annual Meeting 2023 | Oral presentation December 9, 2023
Evaluation of Survival Among Patients With Indolent Systemic Mastocytosis: A Population-Level Retrospective Cohort Analysis Using Healthcare Claims Dataset
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2023 | Poster November 12, 2023
The Burden of Systemic Mastocytosis in the EU: Evidence From the PRISM Patient Survey
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2023 | Poster November 12, 2023
Epidemiology of systemic mastocytosis (SM) and indolent systemic mastocytosis (ISM) in Germany
American College of Allergy, Asthma, and Immunology (ACAAI) | Poster November 11, 2023
American College of Allergy, Asthma, and Immunology (ACAAI) 2023
Avapritinib Improved Gastrointestinal Symptoms in Patients With Indolent Systemic Mastocytosis: Registrational Double-Blind, Placebo-Controlled PIONEER Study
American College of Allergy, Asthma, and Immunology (ACAAI) 2023 | Poster November 10, 2023
Avapritinib
Anaphylaxis in Patients With Indolent Systemic Mastocytosis (ISM): A Severe, Potentially Life-Threatening Complication
Society of Hematologic Oncology (SOHO) 2023 | Poster September 6, 2023
Development of a Diagnostic Algorithm for the Early Identification of Patients with Systemic Mastocytosis
Society of Hematologic Oncology (SOHO) 2023 | Poster September 6, 2023
Avapritinib
Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind Placebo-Controlled PIONEER Trial
2023 Society for Neuro-Oncology (SNO) Pediatric Conference | Oral presentation June 22, 2023
Avapritinib
Clinical response to the PDGFRA/KIT inhibitor Avapritinib in pediatric and young adult high-grade glioma patients with H3K27M or PDGFRA genomic alterations
2023 Society for Neuro-Oncology (SNO) Pediatric Conference | Poster June 22, 2023
Avapritinib
ROVER: A phase 1/2 study of avapritinib in pediatric patients with solid tumors dependent on KIT or PDGFRA signaling
European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress | Poster June 10, 2023
BLU-263
HARBOR: A Phase 2/3 Study of Elenestinib (BLU-263) in Patients with Indolent Systemic Mastocytosis (ISM) and Monoclonal Mast Cell Activation Syndrome (mMCAS)
European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress | Oral presentation June 9, 2023
Symptom and Quality of Life Burden In Patients with Indolent Systemic Mastocytosis
American Society of Clinical Oncology (ASCO) Annual Meeting | Oral presentation June 5, 2023
BLU-945
BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 4, 2023
BLU-451
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 4, 2023
RET Testing and Treatment Patterns among aNSCLC Patients in US Clinical Practice
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 3,2023
Avapritinib
Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: postost hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trial
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 3,2023
BLU-222
BLU-222, an oral, potent and selective CDK2 inhibitor, in patients with advanced solid tumors:
phase 1 monotherapy dose escalation
Eastern Allergy Conference (EAC) 2023 Congress | Poster June 3,2023
Efficacy and Safety of Avapritinib in Indolent Systemic Mastocytosis: Results From the Double Blinded Placebo-Controlled PIONEER Study’
American Association for Cancer Research (AACR) | Poster April 14, 2023
Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Disease Worsening and Progression in Patients with Indolent Systemic Mastocytosis: A US Population-Level Analysis Using Health Claims-Based Dataset
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Symptomatology and Diagnostic Journey of Patients Diagnosed with Systemic Mastocytosis in The US Oncology Network
American Academy of Allergy, Asthma & Immunology (AAAAI) | Oral presentation February 24, 2023
Avapritinib
Avapritinib Improved Skin Findings In Patients With Indolent Systemic Mastocytosis (ISM) In the Registrational, Double-Blind, Placebo-Controlled PIONEER Study
American Academy of Allergy, Asthma & Immunology (AAAAI) | Oral presentation February 24, 2023
Avapritinib
Efficacy and Safety of Avapritinib in Indolent Systemic Mastocytosis (ISM): Results from the Double-Blind Placebo-Controlled PIONEER Study
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Avapritinib
Avapritinib Improved Symptoms and Quality of Life in Patients with Indolent Systemic Mastocytosis in the PIONEER Study
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
PROSPECTOR: A Global, Prospective Study to Determine the Prevalence of the KIT D816V Mutation in Peripheral Blood From Patients With Evidence of Systemic Mast Cell Activation
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Real-world chart pull data on the clinical presentation and diagnosis of indolent systemic mastocytosis
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Development of Scalable, Electronic Health Record (EHR)-Based Screening for Undiagnosed Systemic Mastocytosis: PREDICT-SM
American Academy of Allergy, Asthma & Immunology (AAAAI) | Poster February 24, 2023
Development of a Clinical Scoring System to Identify Conditions of Mast Cell Proliferation in a Community Setting
American Society of Hematology (ASH) Annual Meeting | Poster December 10, 2022
Avapritinib
An Updated Analysis on Safety and Efficacy of Avapritinib in Patients With Advanced Systemic Mastocytosis From the EXPLORER Clinical Study: Long-term Efficacy and Safety
American Society of Hematology (ASH) Annual Meeting | Poster December 10, 2022
BLU-263
AZURE: A Phase 1/2 Study of BLU-263 as Monotherapy and in Combination with Azacitidine in Patients With Advanced Systemic Mastocytosis
American Society of Hematology (ASH) Annual Meeting | Poster December 10, 2022
NGS Testing Practices and Molecular Profile Landscape of the KIT Gene in Systemic Mastocytosis: Real-world Insights From Selected European Countries
American Society of Hematology (ASH) Annual Meeting | Poster December 10, 2022
Disease Progression in Patients with Systemic Mastocytosis: A US Population-Level Analysis Using Health Claims-Based Dataset
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 10, 2022
Avapritinib
Avapritinib as first-line therapy in patients with advanced systemic mastocytosis: Efficacy and safety from the PATHFINDER clinical study
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 6, 2022
BLU-451
A phase 1/2 study of BLU-451, a central nervous system (CNS) penetrant, small molecule inhibitor of EGFR, in incurable advanced cancers with EGFR exon 20 insertion (ex20ins) mutations
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 6, 2022
BLU-701
A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)
American Society of Clinical Oncology (ASCO) Annual Meeting | Poster June 6, 2022
BLU-945
A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non-small cell lung cancer (NSCLC) (SYMPHONY trial-in-progress)
American Society of Clinical Oncology (ASCO) Annual Meeting | Oral presentation June 4, 2022
Avapritinib
Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST)
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
BLU-945 & BLU-701
Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
BLU-945
Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA in the phase 1/2 SYMPHONY study
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
BLU-222
BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
BLU-451
LNG-451 (BLU-451), a potent inhibitor of EGFR exon 20 insertion mutations with high CNS exposure
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
Avapritinib, BLU-5675, & BLU-7444
Efficacy of a highly potent and selective KIT V654A inhibitor for treatment of Imatinib-resistant GIST
American Association for Cancer Research (AACR) Annual Meeting | Poster April 8, 2022
BLU-451
LNG-451 (BLU-451) is a Potent, CNS-Penetrant, Wild-Type EGFR Sparing Inhibitor of EGFR Exon 20 Insertion Mutations
The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting | Poster February 25, 2022
Avapritinib
A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome
The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting | Poster February 25, 2022
Avapritinib
Utility of a Validated Disease-Specific Measure to Assess Symptomology in Patients with Indolent Systemic Mastocytosis (ISM)
The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting | Poster February 25, 2022
Avapritinib
Comorbidity and Disability in Medicare Beneficiaries Newly Diagnosed with Non-Advanced Systemic Mastocytosis (Non-AdvSM)
The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting | Poster February 25, 2022
Avapritinib
Disease Symptomology, Quality of Life (QoL), and Employment Status Among Patients with Systemic Mastocytosis (SM)
British Thoracic Oncology Group (BTOG) Annual Conference | Poster January 28, 2022
BLU-945 & BLU-701
BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer driven by EGFR mutations
American Society of Hematology (ASH) Annual Meeting | Poster December 12, 2021
Avapritinib
Efficacy of Avapritinib in Patients With Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses From the Phase 2 Open-Label, Single-Arm, PATHFINDER Study
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 11, 2021
Avapritinib
Effective Control of Advanced Systemic Mastocytosis with Avapritinib: Mutational Analysis from the EXPLORER Clinical Study
American Society of Hematology (ASH) Annual Meeting | Oral presentation December 9, 2021
Avapritinib
Healthcare Resource Utilization and Costs of Advanced Systemic Mastocytosis Among Medicare Fee for Service Beneficiaries
American Society of Hematology (ASH) Annual Meeting | Poster December 9, 2021
Avapritinib
Healthcare Resource Utilization and Costs of Medicare Fee for Service Beneficiaries Newly Diagnosed with Moderate to Severe Non-Advanced Systemic Mastocytosis
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe | Poster November 30, 2021
Avapritinib
Matching-Adjusted Indirect Comparisons of Avapritinib Versus Midostaurin for the Treatment of Patients with Advanced Systemic Mastocytosis
2021 Society for Neuro-Oncology (SNO) Annual Meeting and Education Day | Poster November 19, 2021
Avapritinib
A phase 1/2 study of avapritinib in pediatric patients with solid tumors dependent on KIT or PDGFRA signaling
American Association for Cancer Research (AACR) Annual Meeting | Oral presentation October 7, 2021
BLU-945
A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)
European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Annual Congress 2021 | Oral presentation July 11, 2021
Avapritinib
Avapritinib improves overall symptoms, skin lesions and quality of life in patients with advanced systemic mastocytosis in the PATHFINDER study
European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer | Oral presentation June 30, 2021
Avapritinib
Safety and Efficacy Results from an Open-label, Multicentre, Phase I/II Study of Avapritinib in Chinese Patients with Gastrointestinal Stromal Tumor (GIST): A Bridging Study of NAVIGATOR
European Hematology Association (EHA) Virtual Congress | Oral presentation June 11, 2021
Avapritinib
Efficacy and safety of avapritinib in patients with advanced systemic mastocytosis: Interim results from the open-label, single-arm, phase 2 PATHFINDER study
2021 Society for Neuro-Oncology (SNO) Pediatric Conference | Poster June 10, 2021
Avapritinib
A phase 1/2, single-arm study to evaluate the safety, pharmacokinetics, and antitumor activity of avapritinib in pediatric patients with solid tumors dependent on KIT or PDGFRA signaling
Academy of Managed Care Pharmacy (AMCP) Annual Meeting | Poster April 12, 2021
Avapritinib
Economic Burden of Advanced Systemic Mastocytosis: A Real-World Evaluation of Direct Healthcare Resource Utilization and Costs from a United States Payer Perspective
Academy of Managed Care Pharmacy (AMCP) Annual Meeting | Poster April 12, 2021
Avapritinib
Healthcare Burden of Patients Newly Diagnosed with Moderate to Severe Non-advanced Systemic Mastocytosis Using a Real-world Database of US Health Plan Members
American Association for Cancer Research (AACR) Annual Meeting | Oral presentation April 11, 2021
Avapritinib
PATHFINDER: Interim analysis of avapritinib in patients with Advanced Systemic Mastocytosis (AdvSM)
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
BLU-222
Development of a selective CDK2-E inhibitor in CCNE-aberrant cancers
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
BLU-852
MAP4K1 inhibition enhances immune cell activation and anti-tumor immunity in preclinical tumor models
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
BLU-945
BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor tyrosine kinase inhibitor with intracranial activity, demonstrates robust in vivo anti-tumor activity in models of osimertinib-resistant non-small cell lung cancer
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
BLU-701
BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
BLU-263
Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in normal healthy volunteers
American Association for Cancer Research (AACR) Annual Meeting | Poster April 10, 2021
Avapritinib
Changes in mast cell numbers and phenotype in patients with indolent systemic mastocytosis treated with avapritinib
Use the filters to view congress data presentations.
The following represents a list of manuscripts published over the past 3 years. These publications are provided for individual, educational purposes for US healthcare professionals only and are not a substitute for consultation and review of reference materials and complete medical literature pertaining to an investigational compound or individual product. Please note that individual publications are only current as of the date listed and may be updated by additional data and/or publications. Please do not copy or distribute further. Further reproduction or distribution is strictly prohibited without permission from the copyright owner(s).
The scientific information may include data on investigational use(s) of compounds for which efficacy and safety have not been established.
World Allergy Organization November 8, 2023
The diagnostic workup for systemic mastocytosis differs from consensus recommendations: Results of a worldwide survey
NAR Cancer July 27, 2023
CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination
Current Research in Translational Medicine July 1, 2023
Avapritinib
Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant
EMJ Hematology June 8, 2023
Untangling Systemic Mastocytosis: An Update on Challenges in the Diagnosis and Treatment of Myeloid Neoplasms with Systemic Mastocytosis
Orphanet Journal of Rare Diseases March 25, 2023
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) and determination of a threshold score for moderate symptoms
Cancer Investigation April 6, 2023
Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry
Annals of Oncology April 25, 2023
Avapritinib
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib
NEJM Evidence May 23, 2023
Avapritinib
Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Future Medicine February 4, 2022
Avapritinib
Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis
Nature Medicine December 6, 2021
Avapritinib
Safety and Efficacy of Avapritinib in Advanced Systemic Mastocytosis: the Phase 1 EXPLORER trial
Nature Medicine December 6, 2021
Avapritinib
Efficacy and Safety of Avapritinib in Advanced Systemic Mastocytosis: Interim Analysis of the Phase 2 PATHFINDER trial
Orphanet October 18, 2021
Psychometric Evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a Phase 2 Clinical Study
Orphanet October 8, 2021
Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF
Journal of Clinical Oncology October 1, 2021
Avapritinib
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
Expert Review of Hematology August 6, 2021
Avapritinib
Avapritinib for Systemic Mastocytosis
The Oncologist April 1, 2021
Avapritinib
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least 3 Prior Lines of Therapy
The Oncologist April 1, 2021
Avapritinib
Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors
BMC Cancer March 1, 2021
Avapritinib
Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data
European Journal of Cancer January 16, 2021
Avapritinib
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Use the filters to view congress data presentations.
